Stoke Therapeutics, Inc.

As of June 30, 2026, Stoke Therapeutics, Inc. carries a market capitalization of 1.77B, placing it among publicly traded companies globally. Its enterprise value stands at 1.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Stoke Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Stoke Therapeutics, Inc. has 62.40M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 72.35, and the price-to-book ratio stands at 5.86.

These figures are as of June 30, 2026. The EV/Sales ratio of 62.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.52B versus a market cap of 1.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Stoke Therapeutics, Inc. maintains a current ratio of 7.69, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Stoke Therapeutics, Inc. posted a negative return on equity (ROE) of -61.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -53.41, reflecting losses generated across the asset base. The company generates approximately 151,396.72 in revenue per employee across its workforce of 159.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Stoke Therapeutics, Inc. recorded an income tax benefit of -1.12M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -183.10M and -181.98M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Stoke Therapeutics, Inc.'s stock has declined approximately 18.12% over the past 52 weeks. The 50-day moving average sits at 24.56, while the 200-day moving average is 26.80.

Over the twelve months ended June 30, 2026, Stoke Therapeutics, Inc. generated 24.15M in revenue and converted that into -181.98M in net income, yielding earnings per share of -2.96. EBITDA reached -194.00M, while operating income came in at -195.52M.

As of June 30, 2026, Stoke Therapeutics, Inc. holds 256.30M in cash and equivalents against 1.61M in total debt, resulting in a net debt position of -96.29M. Total book value stands at 302.46M, with working capital of 245.62M providing operational flexibility.

Stoke Therapeutics, Inc. produced -155.79M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.36M in capital expenditures, free cash flow totaled -158.15M - equivalent to -2.57 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -809.69 and net profit margin of -753.60 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.97, meaning Stoke Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Stoke Therapeutics, Inc. has an Altman Z-Score of 21.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.